TABLE OF CONTENTS
Volume 34, Issue 1 (January 2009)
CNS Drug Discovery and Development: Challenges and Opportunities |
Target Identification |
Target Validation |
Therapeutic Modalities |
Early Clinical Proof-of-Mechanism |
Bridging Proof-of-Mechanism and Efficacy |
Hot Topics
Volume 2
CNS Drug Discovery and Development: Challenges and Opportunities
Commentary: Physician–Scientist's Frustrations Fester
Floyd E Bloom
Neuropsychopharmacology 34: 1-5; doi:10.1038/npp.2008.181
Target Identification
The Medical and Economic Roles of Pipeline Pharmacogenetics: Alzheimer's Disease as a Model of Efficacy and HLA-B*5701 as a Model of Safety
Allen D Roses
Neuropsychopharmacology 34: 6-17; advance online publication, October 15, 2008; doi:10.1038/npp.2008.153
Target Identification for CNS Diseases by Transcriptional Profiling FREE
C Anthony Altar, Marquis P Vawter and Stephen D Ginsberg
Neuropsychopharmacology 34: 18-54; advance online publication, October 15, 2008; doi:10.1038/npp.2008.172
Target Validation
In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination
Jean E Merrill
Neuropsychopharmacology 34: 55-73; advance online publication, September 17, 2008; doi:10.1038/npp.2008.145
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Athina Markou, Christian Chiamulera, Mark A Geyer, Mark Tricklebank and Thomas Steckler
Neuropsychopharmacology 34: 74-89; advance online publication, October 1, 2008; doi:10.1038/npp.2008.173
Non-Human Primates: Model Animals for Developmental Psychopathology
Eric E Nelson and James T Winslow
Neuropsychopharmacology 34: 90-105; advance online publication, September 17, 2008; doi:10.1038/npp.2008.150
Therapeutic Modalities
Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels
Dimitri E Grigoriadis, Samuel R J Hoare, Sandra M Lechner, Deborah H Slee and John A Williams
Neuropsychopharmacology 34: 106-125; advance online publication, September 17, 2008; doi:10.1038/npp.2008.149
Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles FREE
Levi L Blazer and Richard R Neubig
Neuropsychopharmacology 34: 126-141; advance online publication, September 17, 2008; doi:10.1038/npp.2008.151
Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets
Errol B De Souza, Sharon T Cload, Patrick Shannon Pendergrast and Dinah W Y Sah
Neuropsychopharmacology 34: 142-158; advance online publication, August 27, 2008; doi:10.1038/npp.2008.115
Early Clinical Proof-of-Mechanism
Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders
Jose de Leon
Neuropsychopharmacology 34: 159-172; advance online publication, September 17, 2008; doi:10.1038/npp.2008.147
Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Rima Kaddurah-Daouk and K Ranga Rama Krishnan
Neuropsychopharmacology 34: 173-186; advance online publication, October 8, 2008; doi:10.1038/npp.2008.174
The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development FREE
Dean F Wong, Johannes Tauscher and Gerhard Gründer
Neuropsychopharmacology 34: 187-203; advance online publication, October 8, 2008; doi:10.1038/npp.2008.166
Bridging Proof-of-Mechanism and Efficacy
Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders
Philip S Wang, Robert Heinssen, Molly Oliveri, Ann Wagner and Wayne Goodman
Neuropsychopharmacology 34: 204-212; advance online publication, October 1, 2008; doi:10.1038/npp.2008.170
Challenges in Developing Novel Treatments for Childhood Disorders: Lessons from Research on Anxiety FREE
Daniel S Pine, Sarah M Helfinstein, Yair Bar-Haim, Eric Nelson and Nathan A Fox
Neuropsychopharmacology 34: 213-228; advance online publication, August 27, 2008; doi:10.1038/npp.2008.113
NIMH Initiatives to Facilitate Collaborations Among Industry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders
Linda S Brady, Lois Winsky, Wayne Goodman, Mary Ellen Oliveri and Ellen Stover
Neuropsychopharmacology 34: 229-243; advance online publication, September 17, 2008; doi:10.1038/npp.2008.125
Hot Topics
Adult neurogenesis, cell cycle and drug discovery in psychiatry
Robert N Pechnick and Vera Chesnokova
Neuropsychopharmacology 34: 244; doi:10.1038/npp.2008.164
Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse
Linda P Dwoskin and Michael T Bardo
Neuropsychopharmacology 34: 244-246; doi:10.1038/npp.2008.157
RNA editing as a therapeutic target for CNS disorders
Michael V Morabito and Ronald B Emeson
Neuropsychopharmacology 34: 246; doi:10.1038/npp.2008.159
The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?
Toni S Shippenberg
Neuropsychopharmacology 34: 247; doi:10.1038/npp.2008.165
Protein–protein interactions as therapeutic targets in neuropsychopharmacology
Matthew T Reilly, Kathryn A Cunningham and Amarnath Natarajan
Neuropsychopharmacology 34: 247-248; doi:10.1038/npp.2008.167
Promise of mGluR2/3 activators in psychiatry
P Jeffrey Conn and Carrie K Jones
Neuropsychopharmacology 34: 248-249; doi:10.1038/npp.2008.156
Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?
Geoffrey T Swanson
Neuropsychopharmacology 34: 249-250; doi:10.1038/npp.2008.158
Gene expression profiling in blood: new diagnostics in alcoholism and addiction?
R Dayne Mayfield and R Adron Harris
Neuropsychopharmacology 34: 250-251; doi:10.1038/npp.2008.162
From rapid In Vitro screening to rapid In Vivo screening in the drug discovery process
F Ivy Carroll and Richard A Houghten
Neuropsychopharmacology 34: 251-252; doi:10.1038/npp.2008.160
Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes
Oliver J Marston and Lora K Heisler
Neuropsychopharmacology 34: 252-253; doi:10.1038/npp.2008.169
Turning up the pace of ion channel screening in drug discovery
John Dunlop
Neuropsychopharmacology 34: 253; doi:10.1038/npp.2008.163
